Developer docs
API playgroundTry for free, no card

Search company profiles

Intensity Therapeutics

Full company profile

uuid0000bde

Namestring
Intensity Therapeutics
Legal namestring
Intensity Therapeutics, Inc.
Company typeenum
Public
Founded yearint
2012
Descriptiontext

Intensity Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Shelton, Connecticut. The company is developing first-in-class intratumoral cancer therapies based on its proprietary DfuseRx discovery platform, which enables direct injection of drug formulations into solid tumors with high dispersion and cell penetration. Its lead product candidate, INT230-6, is a three-component water-based formulation combining cisplatin, vinblastine sulfate, and the proprietary amphiphilic penetration enhancer SHAO (8-((2-hydroxybenzoyl)amino)octanoate). More than 95% of the active ingredients remain in the injected tumor, reducing systemic toxicity while the localized cell death is intended to trigger a systemic adaptive immune response against both injected lesions and distant micro-metastases. The company has been listed on Nasdaq under the ticker INTS since June 30, 2023, operates with a lean team of approximately 7 employees, and holds 19 issued patents across 41 countries.

The company's clinical program targets underserved oncology indications with limited treatment options. The lead program is the Phase 3 INVINCIBLE-3 study in locally recurrent, inoperable, or metastatic soft tissue sarcoma (paused since March 2025 due to funding), the Phase 2 INVINCIBLE-4 neoadjuvant study in triple-negative breast cancer (TNBC), and the Phase 1/2 IT-01 dose-finding study in multiple refractory solid tumors including pancreatic, bile duct, colorectal, and liver cancers. Over 200 patients have been enrolled in clinical trials since 2017, with reported signals including 71.4% pathological complete response in TNBC when INT230-6 is added to standard of care, a 75% disease control rate in IT-01, and median overall survival of 649-715 days in sarcoma versus 205 days historical control. The platform has been validated through clinical collaborations with Merck (KEYTRUDA combination, 2019), Bristol Myers Squibb (Yervoy combination, 2020), and the National Cancer Institute under a CRADA signed in 2014.

Intensity Therapeutics is pre-revenue and does not currently commercialize any product. Revenue is expected to be generated through pharmaceutical product sales and/or partnership licensing following regulatory approval of INT230-6. As of the most recent disclosures, cash and cash equivalents stood at $10.2 million (Q1 2026) against a 2025 net loss of $11.6 million, with management indicating a runway into Q2 2027. Distribution currently occurs through clinical trial sites (approximately 16 sites planned for INVINCIBLE-4 in the U.S., Switzerland, and France), with no commercial sales infrastructure in place. The company has stated it is actively pursuing partnership or acquisition transactions with larger pharmaceutical companies to advance the program through regulatory approval.

Short descriptiontext

Intensity Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: INTS) developing INT230-6, a proprietary intratumoral injection therapy using its DfuseRx platform to treat refractory solid tumors including sarcoma and triple-negative breast cancer. The company is pre-revenue with no commercial customers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShelton, United States
HQ citystring
Shelton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intratumoral cancer therapy, clinical-stage biotechnology, immuno-oncology drugs, drug delivery platform, solid tumor treatment
Industry2 codes
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Intratumoral Immuno-Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage biotech. If INT230-6 receives regulatory approval, the company would generate revenue through direct pharmaceutical product sales for intratumoral cancer treatment.

intensitytherapeutics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1DfuseRx
Description

Proprietary product discovery technology platform that enables drug compounds to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules

intensitytherapeutics.com
+1 more record
Core offering1 text field

Intensity Therapeutics is a clinical-stage biotechnology company developing INT230-6, a proprietary investigational drug formulation combining cisplatin and vinblastine with the SHAO cell penetration enhancer for direct intratumoral injection into solid tumors. Its DfuseRx platform produces water-based drug solutions that disperse throughout injected tumors and, via localized cell death, activate systemic adaptive immune responses against both injected and non-injected tumors including micro-metastases. INT230-6 is currently in Phase 3 testing for soft tissue sarcoma and Phase 2 testing for triple-negative breast cancer, with next-generation candidate INT33X in preclinical development.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 71.4% pathological complete response (pCR) in TNBC patients receiving INT230-6 plus SOC vs 33% for SOC alone in INVINCIBLE-4 study
+4 more records
Product overview1 text field

Intensity Therapeutics is a clinical-stage biotechnology company developing a proprietary intratumoral cancer therapy platform. The core product is INT230-6, a novel drug formulation combining cisplatin and vinblastine with a cell penetration enhancer (SHAO), administered via direct tumor injection. The company's DfuseRx technology platform enables creation of novel cell-penetrating formulations for solid tumor treatment. INT230-6 is currently undergoing Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, with next-generation product INT33X in preclinical development.

Product and service3 records
1INT230-6
CategoryIntratumoral oncology drug candidate
Description

Lead proprietary investigational product candidate designed for direct intratumoral injection, composed of cisplatin and vinblastine combined with the SHAO penetration enhancer that disperses cytotoxic drugs throughout tumors and enables diffusion into cancer cells. IND authorized by FDA, currently in Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer.

2DfuseRx Platform
CategoryDrug delivery technology platform
Description

Proprietary product discovery technology platform that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules. The platform underpins INT230-6 and the next-generation pipeline asset INT33X.

3INT33X
CategoryPipeline oncology drug candidate
Description

Next-generation product candidate in preclinical development, part of the company's pipeline for intratumoral cancer therapy using the DfuseRx platform.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Conducted subject enrollment and treatment for INVINCIBLE Phase 2 presurgical breast cancer study, evaluating pathological and clinical responses under the direction of Principal Investigator Dr. Angel Arnaout.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-01
Description

Analyzing subject immune responses and conducting biomarker analyses for the INVINCIBLE Phase 2 study. Co-director Dr. Melanie Spears leads the diagnostic development work.

3Bristol Myers Squibb
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-04-14
Description

Clinical collaboration to evaluate INT230-6 in combination with Yervoy (ipilimumab), BMS's anti-CTLA-4 antibody, in patients with breast cancer, liver cancer, and advanced sarcoma. Joint development committee manages the collaboration.

intensitytherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-06-25
Description

Clinical collaboration to evaluate INT230-6 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced pancreatic, bile duct, squamous cell, and non-MSI high colon cancers. Part of the IT-01 KEYNOTE-A10 study arm.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2014-01-01
Description

Cooperative Research and Development Agreement (CRADA) with NCI Vaccine Branch to study efficacy and mechanism of action of Intensity's in situ tumor killing products. Two peer-reviewed publications resulted from this collaboration, including work published in International Journal of Molecular Sciences and OncoImmunology.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Nanobiotix develops NBTXR3 (hafnium oxide nanoparticles) for intratumoral injection to enhance radiotherapy in solid tumors, representing a directly comparable intratumoral modality. Both companies are pursuing local tumor-directed intervention with systemic implications for hard-to-treat solid tumors.

TypeEmerging player
Description

Adaptimmune develops engineered TCR-T cell therapies (afami-cel, lete-cel) for solid tumors including sarcoma. Different modality from Intensity but addresses overlapping sarcoma and refractory solid tumor patient populations.

TypeEmerging player
Description

Iovance develops tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, with FDA-approved lifileucel for melanoma. Different delivery modality (cell therapy vs intratumoral injection) but shares the target indication space of refractory solid tumors.

TypeDirect peer
Description

Candel Therapeutics develops CAN-2409, an intratumoral gene-mediated immunotherapy for prostate cancer and high-grade glioma, sharing Intensity's intratumoral injection approach with viral vector delivery. Both target refractory solid tumors with a local injection mechanism designed to drive systemic immune effects.

TypeDirect peer
Description

Replimune develops intratumoral oncolytic virus therapies (RP1, RP2, RP3) that combine local tumor killing with systemic immune activation, sharing Intensity's mechanism rationale of localized treatment triggering abscopal immune effects in solid tumors. Both companies target similar refractory cancer indications and pursue Big Pharma combination strategies.

TypeBroad incumbent
Description

Merck is a broad oncology incumbent with Keytruda franchise and an existing clinical collaboration with Intensity on INT230-6 combinations. Comparable as the largest immuno-oncology player whose combination strategy defines the standard of care that intratumoral therapies must integrate with.

7Targovax
TypeEmerging player
Description

Targovax develops ONCOS-102, an oncolytic adenovirus for intratumoral injection in mesothelioma and other solid tumors. Shares the intratumoral immunotherapy mechanism of action with Intensity Therapeutics, though focused on different lead indications.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Bristol Myers Squibb is a broad oncology incumbent with Yervoy and Opdivo franchises and an active clinical collaboration with Intensity evaluating INT230-6 combinations. Comparable as a major checkpoint inhibitor sponsor whose assets form the combination backbone for intratumoral therapies.

TypeEmerging player
Description

Phio Pharmaceuticals develops INTASYL self-delivering RNAi technology for intratumoral delivery, including lead asset PH-762 administered intratumorally for solid tumors. Overlapping intratumoral delivery modality for oncology indications with smaller scale and earlier clinical stage than Intensity.

10OncoSec Medical (Sirenomed)
TypeDirect peer
Description

OncoSec develops intratumoral electroporation-delivered IL-12 immunotherapy (TAVO), a directly comparable intratumoral delivery approach for solid tumors including melanoma and breast cancer. Both companies focus on local injection with systemic immune engagement as the core value proposition.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Intensity Therapeutics

Intratumoral Immuno-Oncology Therapeuticsintensitytherapeutics.com

Intensity Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: INTS) developing INT230-6, a proprietary intratumoral injection therapy using its DfuseRx platform to treat refractory solid tumors including sarcoma and triple-negative breast cancer. The company is pre-revenue with no commercial customers.

What Intensity Therapeutics does

Intensity Therapeutics is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in Shelton, Connecticut. The company is developing first-in-class intratumoral cancer therapies based on its proprietary DfuseRx discovery platform, which enables direct injection of drug formulations into solid tumors with high dispersion and cell penetration. Its lead product candidate, INT230-6, is a three-component water-based formulation combining cisplatin, vinblastine sulfate, and the proprietary amphiphilic penetration enhancer SHAO (8-((2-hydroxybenzoyl)amino)octanoate). More than 95% of the active ingredients remain in the injected tumor, reducing systemic toxicity while the localized cell death is intended to trigger a systemic adaptive immune response against both injected lesions and distant micro-metastases. The company has been listed on Nasdaq under the ticker INTS since June 30, 2023, operates with a lean team of approximately 7 employees, and holds 19 issued patents across 41 countries.

The company's clinical program targets underserved oncology indications with limited treatment options. The lead program is the Phase 3 INVINCIBLE-3 study in locally recurrent, inoperable, or metastatic soft tissue sarcoma (paused since March 2025 due to funding), the Phase 2 INVINCIBLE-4 neoadjuvant study in triple-negative breast cancer (TNBC), and the Phase 1/2 IT-01 dose-finding study in multiple refractory solid tumors including pancreatic, bile duct, colorectal, and liver cancers. Over 200 patients have been enrolled in clinical trials since 2017, with reported signals including 71.4% pathological complete response in TNBC when INT230-6 is added to standard of care, a 75% disease control rate in IT-01, and median overall survival of 649-715 days in sarcoma versus 205 days historical control. The platform has been validated through clinical collaborations with Merck (KEYTRUDA combination, 2019), Bristol Myers Squibb (Yervoy combination, 2020), and the National Cancer Institute under a CRADA signed in 2014.

Intensity Therapeutics is pre-revenue and does not currently commercialize any product. Revenue is expected to be generated through pharmaceutical product sales and/or partnership licensing following regulatory approval of INT230-6. As of the most recent disclosures, cash and cash equivalents stood at $10.2 million (Q1 2026) against a 2025 net loss of $11.6 million, with management indicating a runway into Q2 2027. Distribution currently occurs through clinical trial sites (approximately 16 sites planned for INVINCIBLE-4 in the U.S., Switzerland, and France), with no commercial sales infrastructure in place. The company has stated it is actively pursuing partnership or acquisition transactions with larger pharmaceutical companies to advance the program through regulatory approval.

Intensity Therapeutics firmographics

Firmographics
Name
Intensity Therapeutics
Legal name
Intensity Therapeutics, Inc.
Website
https://intensitytherapeutics.com
Company type
Public
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Intensity Therapeutics is a clinical-stage biopharmaceutical company (Nasdaq: INTS) developing INT230-6, a proprietary intratumoral injection therapy using its DfuseRx platform to treat refractory solid tumors including sarcoma and triple-negative breast cancer. The company is pre-revenue with no commercial customers.
Ownership category
akta.pro rank

Intensity Therapeutics industry classification

Industry
Product category
Intratumoral Immuno-Oncology Therapeutics
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAC
Oncology & Hematology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIALAE
Clinical Development (Phase I–III Trial Design & Execution)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Intratumoral cancer therapy
  • Clinical-stage biotechnology
  • Immuno-oncology drugs
  • Drug delivery platform
  • Solid tumor treatment

Where Intensity Therapeutics is headquartered

Location

Headquarters

HQ city
Shelton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Intensity Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage biotech. If INT230-6 receives regulatory approval, the company would generate revenue through direct pharmaceutical product sales for intratumoral cancer treatment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Intensity Therapeutics product offering

Product offering

Core offering

Intensity Therapeutics is a clinical-stage biotechnology company developing INT230-6, a proprietary investigational drug formulation combining cisplatin and vinblastine with the SHAO cell penetration enhancer for direct intratumoral injection into solid tumors. Its DfuseRx platform produces water-based drug solutions that disperse throughout injected tumors and, via localized cell death, activate systemic adaptive immune responses against both injected and non-injected tumors including micro-metastases. INT230-6 is currently in Phase 3 testing for soft tissue sarcoma and Phase 2 testing for triple-negative breast cancer, with next-generation candidate INT33X in preclinical development.

Product overview

Intensity Therapeutics is a clinical-stage biotechnology company developing a proprietary intratumoral cancer therapy platform. The core product is INT230-6, a novel drug formulation combining cisplatin and vinblastine with a cell penetration enhancer (SHAO), administered via direct tumor injection. The company's DfuseRx technology platform enables creation of novel cell-penetrating formulations for solid tumor treatment. INT230-6 is currently undergoing Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer, with next-generation product INT33X in preclinical development.

Differentiator

Problem solved

Functional benefit

Brands

  • DfuseRx: Proprietary product discovery technology platform that enables drug compounds to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules
  • INT230-6

Products and services

  • INT230-6 Lead proprietary investigational product candidate designed for direct intratumoral injection, composed of cisplatin and vinblastine combined with the SHAO penetration enhancer that disperses cytotoxic drugs throughout tumors and enables diffusion into cancer cells. IND authorized by FDA, currently in Phase 3 testing in soft tissue sarcoma and Phase 2 studies in triple-negative breast cancer.
  • DfuseRx Platform Proprietary product discovery technology platform that enables drug compounds including cytotoxic agents to be injected directly into solid tumors with high absorption using novel dispersion and cell penetration enhancer molecules. The platform underpins INT230-6 and the next-generation pipeline asset INT33X.
  • INT33X Next-generation product candidate in preclinical development, part of the company's pipeline for intratumoral cancer therapy using the DfuseRx platform.

Quantifiable outcome

  • 71.4% pathological complete response (pCR) in TNBC patients receiving INT230-6 plus SOC vs 33% for SOC alone in INVINCIBLE-4 study
  • +4 more outcomes

Companies that use Intensity Therapeutics

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Intensity Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Intensity Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • Ottawa Hospital Research Institute (OHRI)coreStrategic or Co-development Partner · 1 March 2021Conducted subject enrollment and treatment for INVINCIBLE Phase 2 presurgical breast cancer study, evaluating pathological and clinical responses under the direction of Principal Investigator Dr. Angel Arnaout.
  • Ontario Institute for Cancer Research (OICR)coreStrategic or Co-development Partner · 1 March 2021Analyzing subject immune responses and conducting biomarker analyses for the INVINCIBLE Phase 2 study. Co-director Dr. Melanie Spears leads the diagnostic development work.
  • Bristol Myers SquibbcoreStrategic or Co-development Partner · 14 April 2020Clinical collaboration to evaluate INT230-6 in combination with Yervoy (ipilimumab), BMS's anti-CTLA-4 antibody, in patients with breast cancer, liver cancer, and advanced sarcoma. Joint development committee manages the collaboration.
  • Merck & Co. (MSD outside US/Canada)coreStrategic or Co-development Partner · 25 June 2019Clinical collaboration to evaluate INT230-6 in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced pancreatic, bile duct, squamous cell, and non-MSI high colon cancers. Part of the IT-01 KEYNOTE-A10 study arm.
  • National Cancer Institute (NCI)/National Institutes of HealthcoreStrategic or Co-development Partner · 1 January 2014Cooperative Research and Development Agreement (CRADA) with NCI Vaccine Branch to study efficacy and mechanism of action of Intensity's in situ tumor killing products. Two peer-reviewed publications resulted from this collaboration, including work published in International Journal of Molecular Sciences and OncoImmunology.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Intensity Therapeutics competitors and assessment

Company assessment

Direct peers

  • Nanobiotix: Nanobiotix develops NBTXR3 (hafnium oxide nanoparticles) for intratumoral injection to enhance radiotherapy in solid tumors, representing a directly comparable intratumoral modality. Both companies are pursuing local tumor-directed intervention with systemic implications for hard-to-treat solid tumors.
  • Candel Therapeutics: Candel Therapeutics develops CAN-2409, an intratumoral gene-mediated immunotherapy for prostate cancer and high-grade glioma, sharing Intensity's intratumoral injection approach with viral vector delivery. Both target refractory solid tumors with a local injection mechanism designed to drive systemic immune effects.
  • Replimune Group: Replimune develops intratumoral oncolytic virus therapies (RP1, RP2, RP3) that combine local tumor killing with systemic immune activation, sharing Intensity's mechanism rationale of localized treatment triggering abscopal immune effects in solid tumors. Both companies target similar refractory cancer indications and pursue Big Pharma combination strategies.
  • OncoSec Medical (Sirenomed): OncoSec develops intratumoral electroporation-delivered IL-12 immunotherapy (TAVO), a directly comparable intratumoral delivery approach for solid tumors including melanoma and breast cancer. Both companies focus on local injection with systemic immune engagement as the core value proposition.

Emerging players

  • Adaptimmune Therapeutics: Adaptimmune develops engineered TCR-T cell therapies (afami-cel, lete-cel) for solid tumors including sarcoma. Different modality from Intensity but addresses overlapping sarcoma and refractory solid tumor patient populations.
  • Iovance Biotherapeutics: Iovance develops tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumors, with FDA-approved lifileucel for melanoma. Different delivery modality (cell therapy vs intratumoral injection) but shares the target indication space of refractory solid tumors.
  • Targovax: Targovax develops ONCOS-102, an oncolytic adenovirus for intratumoral injection in mesothelioma and other solid tumors. Shares the intratumoral immunotherapy mechanism of action with Intensity Therapeutics, though focused on different lead indications.
  • Phio Pharmaceuticals: Phio Pharmaceuticals develops INTASYL self-delivering RNAi technology for intratumoral delivery, including lead asset PH-762 administered intratumorally for solid tumors. Overlapping intratumoral delivery modality for oncology indications with smaller scale and earlier clinical stage than Intensity.

Broad incumbents

  • Merck & Co. Merck is a broad oncology incumbent with Keytruda franchise and an existing clinical collaboration with Intensity on INT230-6 combinations. Comparable as the largest immuno-oncology player whose combination strategy defines the standard of care that intratumoral therapies must integrate with.
  • Bristol Myers Squibb: Bristol Myers Squibb is a broad oncology incumbent with Yervoy and Opdivo franchises and an active clinical collaboration with Intensity evaluating INT230-6 combinations. Comparable as a major checkpoint inhibitor sponsor whose assets form the combination backbone for intratumoral therapies.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Intensity Therapeutics social profiles

Digital presence

Intensity Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Intensity Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

Intensity Therapeutics funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Intensity Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intensity Therapeutics

What does Intensity Therapeutics do?

Intensity Therapeutics is a clinical-stage biotechnology company developing INT230-6, a proprietary investigational drug formulation combining cisplatin and vinblastine with the SHAO cell penetration enhancer for direct intratumoral injection into solid tumors. Its DfuseRx platform produces water-based drug solutions that disperse throughout injected tumors and, via localized cell death, activate systemic adaptive immune responses against both injected and non-injected tumors including micro-metastases. INT230-6 is currently in Phase 3 testing for soft tissue sarcoma and Phase 2 testing for triple-negative breast cancer, with next-generation candidate INT33X in preclinical development.

Is Intensity Therapeutics a public or private company?

Intensity Therapeutics is a public company. It is classified as public and is currently operating.

When was Intensity Therapeutics founded?

Intensity Therapeutics was founded in 2012. It employs 11 to 50 people.

Where is Intensity Therapeutics based?

Intensity Therapeutics is headquartered in Shelton, United States, in the North America region.

How does Intensity Therapeutics make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Intensity Therapeutics's main competitors?

Direct peers on record are Nanobiotix, Candel Therapeutics, Replimune Group and OncoSec Medical (Sirenomed). Emerging players are Adaptimmune Therapeutics, Iovance Biotherapeutics, Targovax and Phio Pharmaceuticals. Broad incumbents are Merck & Co. and Bristol Myers Squibb.

Does Intensity Therapeutics have an API?

No public API is recorded for Intensity Therapeutics.

What industry is Intensity Therapeutics in?

Intensity Therapeutics's product category is Intratumoral Immuno-Oncology Therapeutics. Its primary akta.pro industry code is HLAIAAAC, Oncology & Hematology Pharmaceuticals, with a secondary code of HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Digital JournalQ&A: Experimental cancer therapy controls disease in late-stage patientsIntensity Therapeutics reported Phase 1/2 data for its intratumoral injection drug INT230-6, achieving a 75% disease control rate in late-stage solid tumors. In presurgical triple-negative breast cancer, 5 of 7 patients achieved pathological complete response, versus 3 of 7 with standard therapy. The company plans to advance to Phase 3 trials.The Motley FoolIntensity (INTS) Q3 2026 Earnings Call TranscriptIntensity Therapeutics reported a Q3 2026 net loss of $3.5 million, up 33% from the prior year, with R&D expenses rising 56% to $2.4 million. The company resumed clinical enrollment in its phase III INVINCIBLE-3 and phase II INVINCIBLE-4 studies, with cash of $8.5 million and projected monthly burn of about $1 million in Q4.BenzingaIntensity Therapeutics Q3 2026 Earnings Call Transcript - Intensity Therapeutics (NASDAQ:INTS)Intensity Therapeutics reported a Q3 2026 net loss of $3.5 million, up from $2.7 million in Q3 2025, driven by higher R&D and clinical trial costs. The company resumed patient enrollment in its Phase 3 Invincible 3 and Phase 2 Invincible 4 studies, with $8.5 million in cash and a monthly operating burn expected to rise to $1 million in Q4.TradingViewIntensity Therapeutics (INTS) Reports $3.5M Q3 Net Loss; Enrollment Resumes in Two TrialsIntensity Therapeutics reported a Q3 2026 net loss of $3.5M versus $2.7M a year earlier, with cash of $8.5M at September 30. Enrollment resumed in Phase 3 INVINCIBLE-3 and Phase 2 INVINCIBLE-4 studies, with preliminary pCR rates of 71% and 42% in 14 INVINCIBLE-4 patients. The company plans an independent safety review in Q1 2027.PR NewswireIntensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster PresentatioIntensity Therapeutics will present INVINCIBLE-4 study data for the first seven patients in Cohort A at ESMO 2026. Pathological complete response was achieved in 5 of 7 patients (71%), with no invasive cancer cells in axillary nodes in 6 of 7. The trial is a phase 2 study of INT230-6 plus standard-of-care neoadjuvant immunochemotherapy.American Banking and Market NewsIntensity Therapeutics (NASDAQ:INTS) Stock Price Up 2.1% – What’s Next?Intensity Therapeutics shares rose 2.1% to $3.2070 on Thursday, with a consensus price target of $7.00. Analysts have a Moderate Buy rating, with HC Wainwright raising its price objective to $7.00. The company reported a loss of $1.11 per share for the quarter, missing estimates.Investing.comIntensity Therapeutics at H.C. Wainwright conference: data, cash and catalysts By Investing.comIntensity Therapeutics presented its intratumoral cancer platform at the H.C. Wainwright conference, citing data from over 200 patients. Metastatic data showed median survival of about 12 months versus 4-7 months, and early breast cancer data showed a 71% pathological complete response rate. The company needs about $30 million to reach data readouts through 2028.Stock TitanIntensity Therapeutics to Present at H.C. WainwrightIntensity Therapeutics will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 11, 2026, with CEO Lewis H. Bender available for one-on-one meetings. The company's lead product INT230-6, a non-covalent conjugate of cisplatin and vinblastine, has completed two clinical studies with over 200 patients and a Phase 3 trial is underway.PR NewswireIntensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceIntensity Therapeutics will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026, with a presentation on September 11. The company's lead product INT230-6, a non-covalent conjugate of cisplatin and vinblastine, has completed two clinical studies with over 200 patients and a Phase 3 trial is underway.Markets DailyHead-To-Head Comparison: Clever Leaves (NASDAQ:CLVR) vs. Intensity Therapeutics (NASDAQ:INTS)MarketBeat published a comparative stock analysis of Intensity Therapeutics and Clever Leaves, evaluating them across metrics such as analyst recommendations, valuation, profitability, and risk. The report indicates that while Intensity Therapeutics has a stronger consensus rating with potential upside, Clever Leaves outperformed on seven of the thirteen compared factors.